NSABP C06

A clinical trial comparing oral uracil/ftorfur (UFT) plus leucovorin (LV) with 5-fluorouracil (5-FU) plus LV in the treatment of stages II and III carcinoma of the colon.

Share

Trial Status

Completed

Cancer Type

Colorectal Cancer

Aim

Adjuvant chemotherapy with 5-FU and LV given after surgery improves recurrence and cure rates for people with early colon cancer.  Most chemotherapy is given through a tube into the vein (intra-venous infusion).  UFT is a new chemotherapy drug that is given as a tablet; its effects on the cancer are similar to 5-FU.  This study will determine if using UFT instead of 5-FU will result in people living as long and with better quality of life.

Trial Status

Completed

Cancer Type

Colorectal Cancer

Publication Reference

  1. Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. Journal of Clinical Oncology 2007; 25(4): 424–430.
  2. Lembersky BC, Wieand HS, Petrelli NJ, O’Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral Uracil and Tegafur Plus Leucovorin Compared with Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. Journal of Clinical Oncology 2006; 24(13): 2059-64.

Aim

Adjuvant chemotherapy with 5-FU and LV given after surgery improves recurrence and cure rates for people with early colon cancer.  Most chemotherapy is given through a tube into the vein (intra-venous infusion).  UFT is a new chemotherapy drug that is given as a tablet; its effects on the cancer are similar to 5-FU.  This study will determine if using UFT instead of 5-FU will result in people living as long and with better quality of life.

Principal Investigator

Professor Michael Findlay, Medical Oncologist Auckland Hospital, NZ

Funding

NSABP Inc (USA)